Encoded Therapeutics is a biotechnology company advancing precision medicines for a broad range of genetic disorders.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/24/2021 | Series E | $378.09MM | $xx.xx | $2.13B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
16,631,476
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
07/22/2020 | Series D | $134.95MM | $xx.xx | $630.91MM | Google Ventures, Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management, SoftBank Vision Fund 2 | |
Price per Share
$xx.xx
Shares Outstanding
16,078,670
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Google Ventures, Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management, SoftBank Vision Fund 2
|
||||||
06/26/2019 | Series C | $104MM | $xx.xx | $433.3MM | Venrock, ARCH Venture Partners, Matrix Capital Management, Illumina Ventures, Altitude Life Science Ventures, Menlo Ventures, RTW Investments, Boxer Capital, Alexandria Venture Investments | |
Price per Share
$xx.xx
Shares Outstanding
13,817,834
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Venrock, ARCH Venture Partners, Matrix Capital Management, Illumina Ventures, Altitude Life Science Ventures, Menlo Ventures, RTW Investments, Boxer Capital, Alexandria Venture Investments
|
||||||
12/31/2016 | Series B | $34.25MM | $xx.xx | $160.17MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
8,089,462
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
06/30/2016 | Series A | $15MM | $xx.xx | $38.93MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
10,901,157
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
12/31/2015 | Series Seed-2 | $3.5MM | $xx.xx | $10.81MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,391,246
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
12/31/2015 | Series Seed-1 | $1.09MM | $xx.xx | $10.81MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,099,248
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|